A survey of skull development of the rice rat (Oryzomys palustris natator) covering a period of 21 days to 16 months involving equal numbers of males and females (108) was undertaken using various skull parameters. Sexual dimorphism in relation to body weight and length emerged before that of the skull which was only clearly marked by 2 months. A number of the skull parameters by virtue of their individual growth potential did not show sexual differences in size for a long time, whereas others were clearly marked. Once the differences between the sexes had been established they were maintained. One parameter – length of cranium – represents those parameters which show changes and it was found that the male rat continued to show a steady linear increase in length up to 16 months, whereas the female cranial length shows a deceleration with termination around 12 months. The skull differences are mirrored in the weight and length findings and it suggested that the earlier sexual maturity of the females is compensated by an earlier cessation of growth compared to the males which mature later and have a correspondingly later cessation.

Keywords:
Postweaning rice rat skull, Sexual dimorphism, Assessment of maturity
This content is only available via PDF.
© 1976 S. Karger AG, Basel
1976
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.